Free Trial
NASDAQ:BJDX

Bluejay Diagnostics Q1 2026 Earnings Results & Report

Bluejay Diagnostics logo
$0.82 +0.01 (+0.68%)
Closing price 04:00 PM Eastern
Extended Trading
$0.79 -0.03 (-3.26%)
As of 07:36 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Bluejay Diagnostics reported Q1 2026 earnings on May 7, 2026. The company reported EPS of -$1.95.

Earnings Announcement Details

Quarter
Q1 2026
Report Date
Time
After Market Closes

Bluejay Diagnostics EPS Results

Actual EPS
-$1.95
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Bluejay Diagnostics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Upcoming Earnings

Bluejay Diagnostics' next earnings date is estimated for Friday, November 13, 2026, based on past reporting schedules.

Conference Call Resources

Bluejay Diagnostics Q1 2026 Earnings FAQ

Bluejay Diagnostics (NASDAQ:BJDX) reported earnings of -$1.95 per share for Q1 2026. The report was announced on Thursday, May 7, 2026.

Bluejay Diagnostics' next earnings date is estimated for Friday, November 13, 2026. MarketBeat tracks confirmed and estimated earnings dates for Bluejay Diagnostics on the company's earnings history page.

Bluejay Diagnostics Earnings Headlines

Bluejay Diagnostics, Inc. (NASDAQ:BJDX) Short Interest Update
CODE RED: AI Meltdown Imminent?
After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to trigger the next crash. The research firm Bernstein Research said this AI company has the power to crash the global economy for a decade, the CEO just issued a CODE RED in an internal memo warning employees they're dealing with a critical situation, and another company executive even implied they might need a government bailout. The last time I saw something like this was in 2008 when I predicted a stock market meltdown just three weeks before Lehman went under.tc pixel
See More Bluejay Diagnostics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Bluejay Diagnostics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Bluejay Diagnostics and other key companies, straight to your email.

About Bluejay Diagnostics

Bluejay Diagnostics (NASDAQ:BJDX) is a medical technology company focused on developing rapid, decentralized diagnostic solutions for use at the point of care. The company’s products are designed to help healthcare professionals obtain timely information from blood samples, supporting clinical decision-making in acute-care settings.

Bluejay’s primary technology is the Symphony System, a compact analyzer and disposable testing platform intended to measure clinically relevant biomarkers from whole blood. The system is designed to provide results near the patient rather than requiring samples to be sent to a centralized laboratory. The company has focused its development efforts on applications such as sepsis and other conditions in which rapid assessment may assist with patient management.

Bluejay Diagnostics is based in the United States and has directed its activities primarily toward the U.S. healthcare market. The company continues to develop and advance its Symphony platform and related diagnostic applications for hospitals, emergency departments, and other acute-care environments.

View Bluejay Diagnostics Profile